Cargando…

Immunoprophylaxis against respiratory syncytial virus with palvizumab: what is new?

Detalles Bibliográficos
Autor principal:	Sáfadi, Marco Aurélio P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade de Pediatria de São Paulo 2014
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4183015/ https://www.ncbi.nlm.nih.gov/pubmed/25119743 http://dx.doi.org/10.1590/0103-05822014322

Ejemplares similares

Immunoprophylaxis of respiratory syncytial virus: global experience
por: Simoes, Eric AF
Publicado: (2002)

Patient equity and respiratory syncytial virus Immunoprophylaxis
por: Cody Meissner, H.
Publicado: (2019)

Seasonality in Respiratory Syncytial Virus Hospitalizations and Immunoprophylaxis
por: Kusma, Jennifer D., et al.
Publicado: (2023)

The epidemiology and risk factors of respiratory syncytial virus and its impact on the timing of immunoprophylaxis
por: Jeena, Prakash Mohan
Publicado: (2018)

Passive Immunoprophylaxis against Respiratory Syncytial Virus in Children: Where Are We Now?
por: Rocca, Alessandro, et al.
Publicado: (2021)

Effectiveness of palivizumab immunoprophylaxis in preterm infants against respiratory syncytial virus disease in Qatar
por: Abushahin, Ahmad, et al.
Publicado: (2018)

Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants
por: Blanken, Maarten O., et al.
Publicado: (2017)

Respiratory-syncytial virus immunoprophylaxis on asthma symptoms development in prematurity with bronchopulmonary dysplasia
por: Fang, Li-Ching, et al.
Publicado: (2023)

The Logistics and Coordination of Respiratory Syncytial Virus Immunoprophylaxis Use Among US Pediatric Specialists
por: Wong, Pierre C., et al.
Publicado: (2016)

Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? – a cost-utility analysis
por: Ginsberg, Gary M., et al.
Publicado: (2018)

Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
por: Oliveira, Danielle B.L., et al.
Publicado: (2015)

Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada
por: Mitchell, Ian, et al.
Publicado: (2021)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants
por: Staebler, Suzanne, et al.
Publicado: (2020)

Respiratory Syncytial Virus Disease in Preterm Infants in the US Born at 32–35 Weeks Gestation Not Receiving Immunoprophylaxis
por: Ambrose, Christopher S., et al.
Publicado: (2014)

Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
por: Krilov, Leonard R., et al.
Publicado: (2020)

An update on respiratory syncytial virus
por: Piralla, Antonio, et al.
Publicado: (2023)

Incidence of respiratory syncytial virus infection in children with congenital heart disease undergoing immunoprophylaxis with palivizumab in Pará state, north region of Brazil
por: de Souza, Roseane Porfírio, et al.
Publicado: (2019)

Pathobiology of Respiratory Syncytial Virus (RSV)
por: Tripp, Ralph A., et al.
Publicado: (2020)

Respiratory Syncytial Virus (RSV) Update
por: Krilov, Leonard R., et al.
Publicado: (2022)

The 2014–2015 National Impact of the 2014 American Academy of Pediatrics Guidance for Respiratory Syncytial Virus Immunoprophylaxis on Preterm Infants Born in the United States
por: Kong, Amanda M., et al.
Publicado: (2018)

Active immunoprophylaxis with a synthetic DNA-encoded monoclonal anti-respiratory syncytial virus scFv-Fc fusion protein confers protection against infection and durable activity
por: Schultheis, Katherine, et al.
Publicado: (2020)

A New Role for CXCL4 in Respiratory Syncytial Virus Disease
por: Wiseman, Dexter J., et al.
Publicado: (2020)

Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec: A Multicenter Retrospective Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

RNA Replicons - A New Approach for Influenza Virus Immunoprophylaxis
por: Zimmer, Gert
Publicado: (2010)

The Changing Landscape of Respiratory Syncytial Virus Infections
por: Bem, Reinout A., et al.
Publicado: (2023)

The Respiratory Mucosa: Front and Center in Respiratory Syncytial Virus Disease
por: Thwaites, Ryan S., et al.
Publicado: (2019)

Immunoprophylaxis against important virus diseases of horses, farm animals and birds
por: Patel, J.R., et al.
Publicado: (2009)

Development in Immunoprophylaxis against Rabies for Animals and Humans
por: Nandi, Sukdeb, et al.
Publicado: (2010)

IgY antibodies for the immunoprophylaxis and therapy of respiratory infections
por: Abbas, Aymn Talat, et al.
Publicado: (2018)

Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017
por: Fergie, Jaime, et al.
Publicado: (2020)

Vaccination of Older Adults Against Respiratory Syncytial Virus: The Final Pieces of the Puzzle
por: Atkins, Katherine E, et al.
Publicado: (2023)

Respiratory Syncytial Virus Infection in High-Risk Infants
por: Resch, Bernhard
Publicado: (2011)

Fail-Fast in Respiratory Syncytial Virus Vaccine Development
por: Besteman, Sjanna B., et al.
Publicado: (2019)

Respiratory syncytial virus (RSV) disease – new data needed to guide future policy
por: Campbell, Harry, et al.
Publicado: (2015)

Respiratory Syncytial Virus Hospitalizations among U.S. Preterm Infants Compared with Term Infants Before and After the 2014 American Academy of Pediatrics Guidance on Immunoprophylaxis: 2012–2016
por: Goldstein, Mitchell, et al.
Publicado: (2018)

Effectiveness of palivizumab immunoprophylaxis to prevent respiratory syncytial virus hospitalizations in healthy full-term <6-month-old infants from the circumpolar region of Nunavik, Quebec, Canada
por: Gilca, Rodica, et al.
Publicado: (2020)

Immunoprophylaxis against Mother-to-Child Transmission of HIV-1
por: Gorny, Miroslaw K, et al.
Publicado: (2006)

[Translated article] Where does Respiratory Syncytial Virus Hide?
por: Martinón-Torres, Federico, et al.
Publicado: (2022)

743. Severity and Costs of Respiratory Syncytial Virus and Bronchiolitis Hospitalization in Commercially Insured Preterm and Term Infants Before and After the 2014 American Academy of Pediatrics Guidance Change on Immunoprophylaxis
por: Krilov, Leonard R, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nip0gts6gs0tnvraaaqi59fe3d